U.S. Markets closed

Genentech files flurry of lawsuits to protect $100,000-a-year drug

Ron Leuty
Genentech files flurry of lawsuits to protect $100,000-a-year drug

Genentech bought InterMune and the Brisbane company's idiopathic pulmonary fibrosis drug Esbriet for more than $8 billion in fall 2014. Now it faces pressure from more than a dozen generic drug makers.